Literature DB >> 17052201

Mechanisms regulating energy metabolism by adiponectin in obesity and diabetes.

X Fang1, G Sweeney.   

Abstract

Nutritional control of molecular events has become of great interest given the increased incidence of diet-induced obesity, and consequently Type 2 (non-insulin-dependent) diabetes, in recent years. The altered adipose tissue content in obese individuals results in an altered profile of circulating adipokines, and here we focus on adiponectin, whose circulating levels decrease in obese individuals. Adiponectin is a 30 kDa protein but circulates primarily as hexameric, oligomeric and, to a lesser extent, trimeric forms. Full-length adiponectin can also be cleaved to produce a fragment containing the globular domain that exerts potent metabolic effects. Adiponectin has insulin-mimetic and -sensitizing actions including stimulation of glucose uptake in skeletal muscle and suppression of glucose production in liver. Hence, adiponectin has attracted great interest as an antidiabetic agent. Adiponectin acts via two receptor isoforms, AdipoR1 (adiponectin receptor 1) and AdipoR2, which have distinct tissue distributions and affinities for recognition of the various adiponectin forms. Expression of AdipoR isoforms can be regulated by hyperinsulinaemia and hyperglycaemia with the consequence of increased sensitivity or resistance to specific forms of adiponectin. In summary, regulation of adiponectin or AdipoR expression may be of great importance in the development of metabolic perturbations characteristic of Type 2 diabetes in obese individuals.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17052201     DOI: 10.1042/BST0340798

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  31 in total

Review 1.  Systemic adiponectin malfunction as a risk factor for cardiovascular disease.

Authors:  Wayne Bond Lau; Ling Tao; Yajing Wang; Rong Li; Xin L Ma
Journal:  Antioxid Redox Signal       Date:  2011-04-20       Impact factor: 8.401

2.  Preliminary comparative study on the effect of different chinese drugs for strengthening Pi in antagonizing diet induced obesity.

Authors:  Xiao Li; Ping Jiang; Chang-geng Fu
Journal:  Chin J Integr Med       Date:  2010-05-16       Impact factor: 1.978

Review 3.  The evolving role of adiponectin as an additive biomarker in HFrEF.

Authors:  Tahnee Sente; Andreas Gevaert; An Van Berendoncks; Christiaan J Vrints; Vicky Y Hoymans
Journal:  Heart Fail Rev       Date:  2016-11       Impact factor: 4.214

Review 4.  The role of adiponectin in endothelial dysfunction and hypertension.

Authors:  Edward Rojas; Daloha Rodríguez-Molina; Peter Bolli; Zafar H Israili; Judith Faría; Enzamaría Fidilio; Valmore Bermúdez; Manuel Velasco
Journal:  Curr Hypertens Rep       Date:  2014-08       Impact factor: 5.369

5.  The effects of energy intake of four different feeding patterns in rats.

Authors:  Huan Gong; Yi-wen Han; Liang Sun; Yan Zhang; En-yi Zhang; Yi Li; Tie-mei Zhang
Journal:  Exp Biol Med (Maywood)       Date:  2015-05-12

Review 6.  Direct effects of adipokines on the heart: focus on adiponectin.

Authors:  Min Park; Gary Sweeney
Journal:  Heart Fail Rev       Date:  2013-09       Impact factor: 4.214

7.  Adiponectin downregulation is associated with volume overload-induced myocyte dysfunction in rats.

Authors:  Li-li Wang; Dori Miller; Desiree Wanders; Gayani Nanayakkara; Rajesh Amin; Robert Judd; Edward E Morrison; Ju-ming Zhong
Journal:  Acta Pharmacol Sin       Date:  2015-11-30       Impact factor: 6.150

8.  Adiponectin and leptin metabolic biomarkers in chinese children and adolescents.

Authors:  Jie Mi; Mercedes Nancy Munkonda; Ming Li; Mei-Xian Zhang; Xiao-Yuan Zhao; Ponce Cedric Wamba Fouejeu; Katherine Cianflone
Journal:  J Obes       Date:  2010-10-31

9.  Leptin prevents the metabolic effects of adiponectin in L6 myotubes.

Authors:  X Fang; J Fetros; K E Dadson; A Xu; G Sweeney
Journal:  Diabetologia       Date:  2009-07-28       Impact factor: 10.122

10.  Activation of AT2 receptors prevents diabetic complications in female db/db mice by NO-mediated mechanisms.

Authors:  Fernando P Dominici; Luciana C Veiras; Justin Z Y Shen; Ellen A Bernstein; Diego T Quiroga; Ulrike M Steckelings; Kenneth E Bernstein; Jorge F Giani
Journal:  Br J Pharmacol       Date:  2020-09-13       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.